THE keynote of anticoagulant therapy is prophylaxis-a fact which makes the clinical evaluation of these drugs much more difficult than the assessment of a remedy employed solely for its curative properties. Anticoagulants are used in clinical work mostly with three objectives: (a) for the prevention of thrombus formation, (b) for the prevention of an extension of a pre-existing clot, and (c) for the promotion of its dissolution and organization.
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In a variety of well-defined post-operative conditions these objectives can usually be achieved. Myocardial infarction, however, is a disease of extremes and subject to wide variations: the acute infarct may be fatal within minutes, or it may be silent or so trivial as to escape recognition. The illness does not readily conform to a strict pattern and hence deductions regarding the efficacy of any particular agent designed to modify its course are naturally difficult. The intermediate groups of moderate severity are commonly encountered in hospital practice, and give rise to much uncertainty. For the individual patient complications are largely unpredictable, both in time and in site. Prognosis is influenced by a number of variables, and, furthermore, the character and severity of the disease varies. The mortality rate after a coronary thrombosis is highest in the first few days of the illness, and therefore the longer the delay in securing hospital accommodation, the lower the death-rate for that particular hospital group. Practice varies in different localities and to compare mortality rates for hospitals where conditions are not exactly similar is apt to be fallacious. Present-day knowledge of the action and use of anticoagulants is far from complete.
Our original experience (Tulloch and Gilchrist, 1950) was based on two simultaneous control and treated groups of patients admitted in purely random fashion to two adjoining hospital pavilions, without any attempt at selection. After close analysis we concluded that our two samples were sufficiently homogeneous in respect of age, sex, severity and duration of the illness, to warrant comparison, to justify preliminary conclusions and to encourage a continuation of the investigations. Having now observed 434 consecutive patients, we have not, so far, found it necessary to modify our main conclusions.
Dicoumarol was first employed, later Tromexan (Tulloch and Gilchrist, 1951) , and it now appears that Dindevan (phenylindanedione) has many advantages. Treatment is commenced with heparin, 20,000 units intramuscularly at 8-hourly intervals. This is continued for twenty-four to forty-eight hours, by which time the oral anticoagulant also commenced at the time of the patient's admission to hospital is usually influencing the prothrombin time. In our laboratory the prothrombin times are estimated each morning and the dose of the oral preparation regulated accordingly. Anticoagulants are employed for the first four weeks of the illness, when thrombo-embolic complications are most commonly experienced.
The mortality rate for the control series is 42-2%, as compared with 19-5% for those receiving anticoagulants. Our experience confirms the view that the prophylactic use of these drugs is capable of reducing the death-rate by half during the first six weeks of hospital care following the onset of the acute attack. Similarly, thrombo-embolic complications can be reduced from 26 % to 10 % over the same period, and deaths directly attributable to this cause reach minimal proportions. These findings are in keeping with the latest experience of Wright, Beck and Marple (1954) .
It is sometimes argued that anticoagulants are unnecessary for the mildest attacks of myocardial infarction because 60% of hospital patients survive their six weeks' stay in hospital and many make good and lasting recoveries without the use of these drugs. This attitude takes little account of the needs of the individual patient, whose immediate future is so often treacherous even after a minor attack. Which one of us is so endowed with prophetic powers as to select on the first day of the illness the patient who will make an uncomplicated recovery? All of us have seen patients, mildly affected at the onset, who within a few days have had a major recurrence or experienced some other catastrophe. To delay the use of anticoagulants until a thrombo-embolic complication has occurred is to deny the therapeutic objectives and to court disaster.
Anticoagulants must be used as soon as the diagnosis is established and the severest cases transferred to hospital at the earliest opportunity. It is the badly shocked and gravely ill patient who stands to gain most benefit from this particular course of treatment. Our expetience is that without the help Proceeditngs of the Royal Society of Medicine 8 of anticoagulants 80°/. of patients showing a moderate to severe grade of cardiogenic shock die within six weeks of the onset. Left at home, often with inadequate nursing care, deprived of constant supervision, and often perforce with makeshift arrangemants for treatment during the first critical twenty-four or forty-eight hours, these patients often face greater risks than those entailed by their immediate transfer to hospital. Again, lozal conditions mu3t influence the decision which the practitioner must make in difficult circuM3tances. The prompt u3e of heparin should be encouaged, even before the patient leaves homn.
Just as the exact mechanism of blood clotting remains in doubt, so also the scop9 of the action of the anticoagulants at present in use has yet to be decided. It is true that our expanding knowledge of pharmacological action depends in large part on specialized techniques of investigation not hitherto available and on increasingly refined methods of observation and measurement. Although anticoagulants can be regulated reasonably weU for clinical purposes by prothrombin-tim-estimations, the -range of their activity is not necessarily re3tricted to this particular function. Indeed, there is evidence to suggest that in the reduction of the mortality of the first six weeks anticoagulants may play a part in lessening the evils of the severer grades of cardiogenic shock (Gilchrist, 1952) . At all events the reduction in the mortality rate observed in the treated series of patients is not entirely explicable on a decreased incidence of frank thrombo-embolic episodes. It is unreasonable to decry the u3e of a druy because its actions in man are imperfectly understood.
No one can safely employ these drugs without reliable laboratory control. The one danger is htmorrhage. Broadly speaking, it arises as a result of (a) internal factors peculiar to the patient, in particul ulceration in the alimentary tract, and seriou3 hepatic or renal disease, or (b) external factors concerning local conditions, in particular an inability on the part of the doctor to ensure reliable laboratory-control from day to day. With increasing experience in the handling of these patients, and in regulating the dose of the oral preparation as determined by strict laboratory control, difficulties are seldom encountered. In our series heamorrhage has only been noted in 11 /Y of the treated group.
In 2 patients, observed eariy in the series, bleeding undoubtedly contributed to death. Hematuria, epistaxis, or haemoptysis occasionally occurs in a mild form and soon subsides when the anticoagulant i reduced or discontinued for a day or two. If the prothrombin time is unduly prolonged, it is usually recommended to employ water-soluble vitamin K in a dose of 60 mg. or more intravenously when heemorrhage occurs, but we have seldom found it necessary. CONCLUSIONS Anticoagulants make a contribution to the prevention ofunpredictable catastrophes in a disease characterized by much uncertainty and by a high mortality rate in the first six weeks of hospital treatment. They are not an infallible remedy but their employment is justified by a halving of the death-rate and by an even greater reduction in thrombo-embolic episodes.
With reliable laboratory control for the day-to-day regulation of the dosage of these drugs, serious hemorrhage is seldom encountered and no harm results from their use.
The employment of anticoagulants has widened our outlook on the problems of acute myocardial infarction and has revealed our therapeutic shortcomings. There is still much to learn regarding the immediate effects of these drugs and their long-term influence. REFERENCES GILCiHRIsT, A. R. (1952) Brit. med. J., ii, 351. TULLOCH, J. A., and GrLcsnusr, A. R. (1950) Brit. med. J., ii, 965; (l951)Amer.'Heart1J.,w42, 864.
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Anticoagulant Therapy in Coronary Occlusion
By WILLIAM EVANS, M.D., D.Sc.. F.R.C.P. BEFoRE turning to deal directly with anticoagulant teatment in coronary occlusion, there is a need co define conditions that should govern the acceptance by the profession of a particular medicine as orthodox in the treatment of any ailment. That a patient should have faith in medicine is an admirable thing; it helps him to get well. A doctor's faith in a remedy, however, should be founded on premises other than a simple hope that it will do good, and on a reliance gained from a clinical trial scientifically controlled. EVen if we admit the influence of fashion on therapeutics we must never change a form of treatment just because it is fashionable. to change.
It is better for a new remedy to be reoeived with a quiet scepticism than with a boundless enthusiasm, because a wiser judgment on its real and lasting benefit is more likely to follow. There ar many reasons why a new remedy is hailed with undue enthusiasm. Among them are the desperate need to ltleviate or cure some fell disease, the demonstration of a specific effect in the experimental animal, the comp'elling advertise. ment which appears to brook no contradiction, its warm recommendation by a medical colleague, based too often on a limited experience, its acceptance by another country politically in the ascendancy, the truism that it is always the latest song that an audience applauds the most-a sentiment born on the lips of Homerand the deniiands-made by either ipatient or relative. There is evidence that we are losing our sef-relianee and that we yield too easily to the whims and fancies of our times and our patients. One of the main functions of a doctor is to manage his patients, and when the patients manage their doctors, and there are ominous
